Pacira named a top pick for 2024 at H.C. Wainwright

H.C. Wainwright names Pacira BioSciences a top pick for 2024 and reiterates a Buy rating on the shares with a $57 price target. The stock is trading near 10-year lows and near all-time low forward multiples, the analyst tells investors in a research note. The firm believes there is a “compelling disconnect” between the current valuation and the company’s “robust cash flows, low leverage, and likely a very long exclusivity runway.”